Report
Valens Research

PBH - Embedded Expectations Analysis - 2018 08 02

Prestige Brands Holdings, Inc. (PBH:USA) is currently trading near historical lows relative to UAFRS-based (Uniform) Earnings, with a 13.4x Uniform P/E. At these levels, the market has bearish expectations for the firm, driven by concerns surrounding their dependence on growth through acquisition and a ballooning balance sheet

Specifically, the market appears concerned about PBH's slow organic growth, and subsequent reliance on M&A to maintain growth. Additionally, the market may lack confidence in PBH's ability to find acquisition targets given the substantial amount of debt already on their balance sheet
Underlying
Prestige Consumer Healthcare Inc

Prestige Consumer Healthcare is a holding company. Through its subsidiaries, the company develops, manufactures, markets, sells and distributes over-the-counter (OTC) healthcare products to mass merchandisers and drug, food, dollar, convenience, and club stores in North America (the U.S. and Canada) and in Australia and certain other international markets. The company's portfolio of OTC Healthcare products includes, among others, DenTek oral care products, Monistat women's health products, Nix lice treatment products, Chloraseptic sore throat treatments, Clear Eyes eye care products, Compound W wart treatments, Luden's throat drops, BC and Goody's pain relievers and Debrox earwax remover.

Provider
Valens Research
Valens Research

In 2009, just as the dust was settling from the last major equity and credit market crises, we launched a boutique research firm with the intention of breaking Wall Street’s biases and broken incentives:

  • GAAP and IFRS have failed to provide rules for reliable financial statement reporting
  • Stock analyst recommendations are not grounded in disciplined financial analysis
  • Credit agencies have been set up to grossly fail in their responsibilities to investors and the public markets
  • Utter lack of willingness of major research firms to employ the the most advanced forensic analysis available

We sought to provide investors and company analysts with a source of information that changed all that.
Many years later, our business model remains because little has changed on Wall Street.

  • Corporate credit ratings remain years behind the fundamental underpinnings of company performance
  • Stock analysts continue to make recommendations with deeply inherent biases
  • Research firms have failed to break down the walls between credit, equity, and macroeconomic research
  • The governing accounting bodies have created more leeway for mis-estimates and mis-classifications as financials have become unwieldy and overwhelming

The integrity of Valens Research is founded in our disciplined processes and analytics. No “star” analysts. No corporate advisory relationships. No-nonsense opinions and recommendations.

Analysts
Valens Research

Other Reports on these Companies
Other Reports from Valens Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch